Skip to content

Study · Other design · 2010

2 results

Preclinical studies with IRX-2 and thymosin alpha1 in combination therapy.

Naylor PH, Hadden JW

Annals of the New York Academy of Sciences1 Apr 2010Cited by 5 (Europe PMC)

PMID20536465 (opens in a new tab)DOI10.1111/j.1749-6632.2010.05475.x (opens in a new tab)PepBankPUB-20536465
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalOther designEfficacy outcome

    In animals given chemotherapy, IRX-3 (IRX-2 plus Talpha1) further enhanced the reduction in tumor burden compared with IRX-2.

    In plain wordsIn animals given chemotherapy, adding thymosin alpha1 to IRX-2 reduced tumor burden more than IRX-2 alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseTumor burden after chemotherapy
    Study

    n: not reported in source

    Comparator
    IRX-2
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    IRX-3 further enhanced reduction in tumor burden following chemotherapy compared to IRX-2.
    1 context sentence
    Summary · context
    In animal studies, the combination of IRX-2 and Talpha1 (IRX-3) increased T-cell numbers compared to either alone during recovery from hydrocortisone mediated reduction.

Studies that did not test the peptide alone1

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 02AnimalNot a test of Thymosin alpha-1 aloneOther designEfficacy outcome

    In animals recovering from hydrocortisone-mediated T-cell reduction, the combination of IRX-2 and Talpha1 (IRX-3) increased T-cell numbers compared with either alone.

    In plain wordsIn animals, the combination IRX-3 raised T-cell numbers more than either of its two parts alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseT-cell numbers during recovery from hydrocortisone-mediated reduction
    Study

    n: not reported in source

    Comparator
    IRX-2 alone or Talpha1 alone
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    In animal studies, the combination of IRX-2 and Talpha1 (IRX-3) increased T-cell numbers compared to either alone during recovery from hydrocortisone mediated reduction.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.